Cytomx Therapeutics, INC. (CTMX) — SEC Filings

Overview

Cytomx Therapeutics, INC. (CTMX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: CytomX Therapeutics, Inc. (CTMX) reported a significant decline in revenue and a net loss for the three months ended September 30, 2025, with revenues plummeting to $5.963 million from $33.432 million in the prior year, a 82.1% decrease. The company posted a net loss of $14.229 million, or $(0.09) p

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 3 bearish, 29 neutral. The dominant filing sentiment for Cytomx Therapeutics, INC. is neutral.

Filing Type Overview

Cytomx Therapeutics, INC. (CTMX) has filed 6 10-Q, 12 8-K, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 2 SC 13G, 1 DEFA14A with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (32)

• CytomX Q3 Revenue Plunges 82% Amidst Net Loss, Bolstered by Equity Raise — 10-Q · Nov 6, 2025 Risk: high
  CytomX Therapeutics, Inc. (CTMX) reported a significant decline in revenue and a net loss for the three months ended September 30, 2025, with revenues plummetin
• CytomX Therapeutics Files 8-K — 8-K · Aug 13, 2025 Risk: low
  On August 13, 2025, CytomX Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is no
• CytomX Losses Widen Amid R&D Spend, Revenue Dip — 10-Q · Aug 7, 2025 Risk: high
  CytomX Therapeutics, Inc. reported a net loss of $39.5 million for the three months ended June 30, 2025, a significant increase from the net loss of $28.7 milli
• CytomX Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 13, 2025 Risk: medium
  CytomX Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting on events that occurred on June 11, 2025. The filing covers the departure of directors or cer
• CytomX Therapeutics Files 8-K — 8-K · May 28, 2025 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 28, 2025, reporting an event on May 27, 2025. The filing is categorized under 'Other Events' and does not specify
• CytomX Therapeutics Files 8-K — 8-K · May 13, 2025 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting other events and financial statements. The filing date indicates the report was submitted on M
• CytomX Therapeutics Files 8-K on Financials and Operations — 8-K · May 12, 2025 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also
• CytomX Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  CytomX Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its ongoing collaborations, including agreements with Amg
• CytomX Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  CytomX Therapeutics, Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting of stockholders on June 11, 2025. The filing outlines t
• CytomX Therapeutics Files 2024 10-K — 10-K · Mar 6, 2025 Risk: medium
  CytomX Therapeutics, Inc. filed its 2024 10-K on March 6, 2025, reporting on its fiscal year ending December 31, 2024. The company is involved in pharmaceutical
• CytomX Therapeutics Faces Listing Rule Issues — 8-K · Feb 26, 2025 Risk: high
  CytomX Therapeutics, Inc. filed an 8-K on February 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with th
• CytomX Therapeutics Appoints New CMO, CSO, and Directors — 8-K · Feb 3, 2025 Risk: medium
  CytomX Therapeutics, Inc. announced on January 30, 2025, changes in its executive and director roles. Dr. Sean E. MacLeod has been appointed as the new Chief Me
• CytomX Therapeutics Reports Exit/Disposal Costs — 8-K · Jan 6, 2025 Risk: medium
  CytomX Therapeutics, Inc. filed an 8-K on January 6, 2025, to report on cost associated with exit or disposal activities. The filing does not contain specific d
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• CytomX Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  CytomX Therapeutics, Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company reported financial results and provided updates on its
• CytomX Therapeutics Q2 2024 Update — 10-Q · Aug 8, 2024 Risk: medium
  CytomX Therapeutics, Inc. filed its Q2 10-Q report for the period ending June 30, 2024. The company's financial statements reflect its ongoing operations in the
• CytomX Therapeutics Announces Board and Executive Changes — 8-K · Jun 17, 2024 Risk: low
  CytomX Therapeutics, Inc. announced on June 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departur
• SC 13G Filing — SC 13G · May 22, 2024
• CytomX Therapeutics Files 8-K on Corporate Matters — 8-K · May 17, 2024 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 17, 2024, reporting on events that occurred on May 15, 2024. The filing indicates a change in the company's fiscal
• SC 13G Filing — SC 13G · May 13, 2024
• CytomX Therapeutics Files 8-K — 8-K · May 8, 2024 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting other events and financial statements. The filing details the company's principal executive off
• CytomX Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
  CytomX Therapeutics, Inc. (CTMX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. CytomX Therapeutics, Inc. filed a 10-Q report for the quarter ende
• CytomX Therapeutics Files Proxy Statement Supplement — DEFA14A · May 1, 2024 Risk: low
  CytomX Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) proxy statement on May 1, 2024. This filing supplements their previous proxy stateme
• CytomX Therapeutics to Hold 2024 Annual Meeting of Stockholders on May 15, 2024 — DEF 14A · Apr 4, 2024 Risk: low
  CytomX Therapeutics, Inc. (CTMX) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. CytomX Therapeutics, Inc. will hold its 2024 Annual Meeting of
• CytomX Therapeutics Announces Board and Executive Changes — 8-K · Mar 22, 2024 Risk: low
  CytomX Therapeutics, Inc. announced on March 20, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Steven D. Agger was appoi
• CytomX Therapeutics Files 2023 10-K — 10-K · Mar 11, 2024 Risk: medium
  CytomX Therapeutics, Inc. filed its 2023 10-K on March 11, 2024, reporting on its fiscal year ending December 31, 2023. The company is involved in pharmaceutica
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024

Risk Profile

Risk Assessment: Of CTMX's 23 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cytomx Therapeutics, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $5.963M
• Net Income: $(14.229)M
• EPS: $(0.09)
• Cash Position: $34.185M
• Total Assets: $158.254M

Key Executives

• Dr. Sean E. MacLeod
• Dr. Michael J. Ybarra
• Mr. David J. E. Smith
• Sean A. McCarthy
• Dr. Steven D. Agger

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like CytomX rely heavily on innovation, clinical trial success, and strategic partnerships for revenue generation and market access. The competitive landscape is intense, with numerous players vying for breakthroughs in oncology and other therapeutic areas.

Top Tags

collaboration (5) · sec-filing (4) · Biotechnology (3) · governance (3) · financials (3) · pharmaceuticals (3) · 10-Q (3) · Oncology (2) · Net Loss (2) · 8-k (2)

Key Numbers

• Q3 2025 Revenue: $5.963M — Down 82.1% from $33.432M in Q3 2024
• Q3 2025 Net Loss: $(14.229)M — Compared to $5.736M net income in Q3 2024
• Nine-Month 2025 Net Income: $9.142M — Down from $12.993M in nine-month 2024
• Net Proceeds from Follow-on Offering: $93.373M — Significantly boosted additional paid-in capital
• Total Stockholders' Equity: $107.389M — Improved from a deficit of $(456)K at Dec 31, 2024
• Short-term Investments: $109.441M — Increased from $62.571M at Dec 31, 2024
• Cash and Cash Equivalents: $34.185M — Decreased from $38.052M at Dec 31, 2024
• Accumulated Deficit: $682.437M — Increased from $691.579M (less negative) at Dec 31, 2024
• Common Shares Outstanding: 165,069,647 — As of September 30, 2025, significantly increased from 80,099,889 at Dec 31, 2024
• Q3 Revenue Decrease: 82.1% — Year-over-year decline for the three months ended September 30, 2025
• SEC File Number: 001-37587 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 27-3521219 — Company's tax identification number.
• Net Loss: $39.5M — for Q2 2025, increased from $28.7M in Q2 2024
• Collaboration Revenue: $14.2M — for Q2 2025, decreased from $18.5M in Q2 2024
• Research and Development Expenses: $38.1M — for Q2 2025, increased from $35.2M in Q2 2024

Related Companies

BMY · REGN · AMGN · ALPMY · MRNA

Frequently Asked Questions